Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (MURGY) Q2 2025 Earnings Call Transcript

Munich Re reported a robust H1 2025 net result of EUR 3.2 billion, firmly positioning the company to achieve its EUR 6 billion full-year target, driven by strong performance across all business lines and a nearly 20% return on equity. P&C Reinsurance and Global Specialty Insurance delivered solid Q2 results, compensating for Q1 losses, with the P&C segment experiencing a modest 1% risk-adjusted price decline in 2025 renewals while maintaining attractive margins. Despite lowering its insurance revenue guidance by EUR 2 billion due to currency fluctuations and strategic portfolio adjustments, the company affirmed its full-year earnings target, emphasizing a continued focus on diversifying into less cyclical segments and its strong 287% Solvency II ratio.

Analysis

Munich Re demonstrated robust operational performance in the first half of 2025, delivering a net result of €3.2 billion and a return on equity of nearly 20%, keeping it firmly on track for its €6 billion full-year profit target. A key development is the company's ability to reaffirm this bottom-line guidance despite lowering its full-year insurance revenue forecast by €2 billion, a move attributed to adverse currency effects from a depreciating U.S. dollar and deliberate, active cycle management. This signals strong underwriting discipline and confidence in underlying profitability. The P&C Reinsurance segment was a standout, with a remarkably low Q2 combined ratio of 61% that compensated for Q1's major losses, supported by a benign loss environment and reserve releases from prior years. While the 2025 renewals saw a modest risk-adjusted price decline of 1.2%, management characterized the market as stabilizing at healthy levels rather than entering a broad soft cycle. The firm's strategic pivot to reduce dependency on P&C Re is evident, with its primary insurance arm, ERGO, delivering a net result of almost €500 million, and its Life & Health and Global Specialty Insurance (GSI) segments showing strong technical results. The company's capital position remains solid with a 287% Solvency II ratio, and it continues to benefit from reinvesting new money at yields around 4.2% to 4.5%.

Key Decisions for Investors

• Investors should focus on the reaffirmed €6 billion profit guidance and high return on equity as primary indicators of strength, viewing the revenue guidance cut as evidence of disciplined underwriting rather than a fundamental business slowdown.
• It is prudent to monitor the P&C reinsurance pricing environment in upcoming renewals and the impact of the North Atlantic hurricane season, as the modest margin compression of 1.2% signals a potential shift in market dynamics that requires continued discipline to navigate.
• Evaluate the execution of the diversification strategy, particularly the growth and profitability of the ERGO and Global Specialty Insurance segments, as their performance is crucial for de-risking the earnings profile and supporting future dividend growth and share buybacks.